

# Human IFN-γ Fluorescein-conjugated Antibody

Monoclonal Mouse IgG<sub>2B</sub> Clone # 25723

Catalog Number: IC285F

100 TESTS


DESCRIPTION			
Species Reactivity	Human		
Specificity	Detects human IFN-γ in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant mouse IFN-γ, recombinant rat IFN-γ, or recombinant porcine IFN-γ is observed.		
Source	Monoclonal Mouse IgG <sub>2B</sub> Clone # 25723		
Purification	Protein A or G purified from hybridoma culture supernatant		
Immunogen	E. coli-derived recombinant human IFN-γ Gln24-Gln166 Accession # AAP20098.1		
Conjugate	Fluorescein Excitation Wavelength: 488 nm Emission Wavelength: 515-545 nm		
Formulation	Supplied in a saline solution containing BSA and Sodium Azide. See Certificate of Analysis for details.		
	*Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Shee (SDS) for additional information and handling instructions.		

#### **APPLICATIONS**

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

	Recommended Concentration	Sample
Intracellular Staining by Flow Cytometry	10 μL/10 <sup>6</sup> cells	See Below

### DATA



Detection of IFN-y in Human PBMCs by Flow Cytometry. Human peripheral blood mononuclear cells (PBMCs) treated with PMA/ionomycin overnight were stained with Mouse Anti-Human IFN-γ Fluoresceinconjugated Monoclonal Antibody (Catalog # IC285F) and Mouse Anti-Human CD3s APCconjugated Monoclonal Antibody (Catalog # FAB100A). Quadrant markers were set based on control antibody staining (Catalog # IC0041F). To facilitate intracellular staining, cells were fixed with Flow Cytometry Fixation Buffer (Catalog # FC004) and permeabilized with Flow Cytometry Permeabilization/Wash Buffer I (Catalog # FC005). View our protocol for Staining Intracellular Molecules.

## PREPARATION AND STORAGE

Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below

Stability & Storage

Protect from light. Do not freeze.

• 12 months from date of receipt, 2 to 8 °C as supplied.





## Human IFN-γ Fluorescein-conjugated Antibody

Monoclonal Mouse  $IgG_{2B}$  Clone # 25723

Catalog Number: IC285F

100 TESTS

### BACKGROUND

Interferon-gamma (IFN- $\gamma$ ), also known as type II or immune interferon, exerts a wide range of immunoregulatory activities and is considered to be the prototype proinflammatory cytokine (1, 2). Mature human IFN- $\gamma$  exists as a non-covalently linked homodimer of 20-25 kDa variably glycosylated subunits (3). It shares 90% amino acid (aa) sequence identity with rhesus IFN- $\gamma$ , 59-64% with bovine, canine, equine, feline, and porcine IFN- $\gamma$ , and 37-43% with cotton rat, mouse, and rat IFN- $\gamma$ . IFN- $\gamma$  dimers bind to IFN- $\gamma$  RII (alpha subunits) which then interact with IFN- $\gamma$  RII (beta subunits) to form the functional receptor complex of two  $\alpha$  and two  $\beta$  subunits. Inclusion of IFN- $\gamma$  RII increases the binding affinity for ligand and the efficiency of signal transduction (4, 5). IFN- $\gamma$  is produced by a variety of immune cells under inflammatory conditions, notably by T cells and NK cells (6). It plays a key role in host defense by promoting the development and activation of Translation of IFN- $\gamma$  monocytes and macrophages, upregulation of antigen presentation molecules, and immunoglobulin class switching in B cells. It also exhibits antiviral, antiproliferative, and apoptotic effects (6, 7). In addition, IFN- $\gamma$  functions as an anti-inflammatory mediator by promoting the development of regulatory T cells and inhibiting Th17 cell differentiation (8, 9). The pleiotropic effects of IFN- $\gamma$  contribute to the development of multiple aspects of atherosclerosis (7).

#### References:

- 1. Billiau, A. and P. Matthys (2009) Cytokine Growth Factor Rev. 20:97.
- 2. Pestka, S. et al. (2004) Immunol. Rev. 202:8.
- 3. Gray, P.W. and D.V. Goeddel (1982) Nature 298:859.
- 4. Marsters, S.A. et al. (1995) Proc. Natl. Acad. Sci. USA 92:5401.
- 5. Krause, C.D. et al. (2000) J. Biol. Chem. 275:22995.
- Schroder, K. et al. (2004) J. Leukoc. Biol. 75:163.
- 7. McLaren, J.E. and D.P. Ramji (2009) Cytokine Growth Factor Rev. 20:125.
- 8. Muhl, H. and J. Pfeilschifter (2003) Int. Immunopharmacol. 3:1247.
- 9. Kelchtermans, H. et al. (2008) Trends Immunol. 29:479.

